
How the Universe and Its Mirrored Version Are Different
Jun 22, 2025 7:00 AM From living matter to molecules to elementary particles, the world is made of 'chiral' objects that differ from their reflected forms. Illustration: Celsius Pictor for Quanta Magazine
The original version of this story appeared in Quanta Magazine.
After her adventures in Wonderland, the fictional Alice stepped through the mirror above her fireplace in Lewis Carroll's 1871 novel Through the Looking-Glass to discover how the reflected realm differed from her own. She found that the books were all written in reverse, and the people were 'living backwards,' navigating a world where effects preceded their causes.
When objects appear different in the mirror, scientists call them chiral. Hands, for instance, are chiral. Imagine Alice trying to shake hands with her reflection. A right hand in mirror-world becomes a left hand, and there's no way to align the two perfectly for a handshake because the fingers bend the wrong way. (In fact, the word 'chirality' originates from the Greek word for 'hand.')
Alice's experience reflects something deep about our own universe: Everything is not the same through the looking glass. The behavior of many familiar objects, from molecules to elementary particles, depends on which mirror-image version we interact with. Mirror Milk
At the beginning of Through the Looking-Glass , Alice holds her cat Kitty up to the mirror and threatens to push her through to the other side. 'I wonder if they'd give you milk in there? Perhaps Looking-glass milk isn't good to drink,' she says.
Alice was onto something. Just over two decades before the book's publication, Louis Pasteur discovered while experimenting with some expired wine that certain molecules can be chiral. They can come in distinct left-handed and right-handed structural forms that are impossible to superimpose. Pasteur found that, while they contain all the same components, the mirror versions of chiral molecules can serve distinct chemical functions.
The pioneering French chemist and microbiologist Louis Pasteur discovered the chirality of biomolecules in the late 1840s. Photograph: Smithsonian Institution Librarie
Lactose, the sugar found in milk, is chiral. While either version can be synthesized, the sugars produced and consumed by living organisms are always the right-handed ones. In fact, life as we know it uses only right-handed sugars—hence why the genetic staircase of DNA always twists to the right. The root of this 'homochirality' remains one of the biggest mysteries clouding the origins of life.
Kitty couldn't have digested looking-glass milk. Worse, if it had contained any bacteria with the opposite handedness, her immune system and antibiotics would have been ill suited to put up a fight. A group of prominent scientists recently cautioned against the synthesis of mirror-image lifeforms for this reason—if any were to escape the lab, they could evade regular lifeforms' defense mechanisms. Shrinking Down
Continuing down the rabbit hole, we see traces of chirality all the way to elementary particles.
Pasteur's work on molecules rested on a previous discovery by Augustin-Jean Fresnel, who in 1822 realized that different quartz prisms could send light's electric field twirling in one of two directions—clockwise or counterclockwise. If each particle of light could leave a smoke trail in its wake, a right-handed screw of smoke would emerge from one prism and a left-handed screw from another.
Nowadays, physicists consider chirality a fundamental property of all elementary particles, just like charge or mass. The particles that don't have mass are always traveling at the speed of light, and they also all carry an intrinsic angular momentum as though they're spinning like a top. If the particles are flying in the direction of your thumb, their spin follows the direction your fingers curl—on either your right hand or your left.
The situation is a bit more complicated for massive particles, such as electrons and quarks. Because a massive particle travels more slowly, a speedy observer could overtake it and effectively reverse its direction of motion, thus flipping its apparent handedness. For this reason, when describing the chirality of massive particles, physicists often refer to the mathematical description of the particle's quantum properties. When you rotate a particle, its quantum wave function shifts left or right depending on its chirality.
Almost every elementary particle has a twin through the looking glass. A negatively charged left-handed electron is mirrored by the anti-positron, a negatively charged right-handed particle.
In looking-glass world, Alice finds all logic turned on its head: People run in order to stay in place, and they celebrate 'un-birthdays' on all the days they weren't born. Similarly, our universe differs from its mirror image. The weak force—the force that's responsible for radioactive decay—is felt only by left-handed particles. This means that some particles will decay in the normal world while their counterparts in the mirror would not.
Plus, there's one particle that seems not to show up in the mirror at all. The neutrino has only ever been observed in its left-handed form. Particle physicists are investigating whether the right-handed neutrino exists or if neutrinos' mirror images are simply identical, which could help explain why the universe contains something rather than nothing.
There's a lot we can learn about our own world by peering through the looking glass. Just be careful not to drink the milk.
Original story reprinted with permission from Quanta Magazine, an editorially independent publication of the Simons Foundation whose mission is to enhance public understanding of science by covering research developments and trends in mathematics and the physical and life sciences.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
By Deena Beasley (Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said. (Reporting By Deena Beasley, Editing by Franklin Paul)
Yahoo
an hour ago
- Yahoo
If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This
Cathie Wood, founder, CEO and chief investment officer of Ark Invest, continues to make headlines for her high-conviction approach to disruptive innovation. Her flagship fund, the Ark Innovation ETF (ARKK), has posted a 52.9% return in the past 52 weeks, reflecting investor confidence. Known for identifying transformational themes early, Wood maintains focused exposure to industries like genomics, autonomous technology, and blockchain. Within this context, Natera (NTRA) has drawn sharp relevance. The company leads in cell-free DNA testing and precision medicine, aligning directly with Ark's long-term thesis. CoreWeave Just Revealed the Largest-Ever Nvidia Blackwell GPU Cluster. Should You Buy CRWV Stock? AMD Is Gunning for Nvidia's AI Chip Throne. Should You Buy AMD Stock Now? The Saturday Spread: Statistical Signals Flash Green for CMG, TMUS and VALE Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For investors seeking a stock that fits the Ark playbook, Natera may represent one of the most fundamentally aligned additions under Wood's current investment lens. Based in Austin, Texas, stands Natera (NTRA), a pioneer in the field of cell-free DNA and genetic testing. The $23.3 billion biotech firm's arsenal includes powerful offerings like Panorama for prenatal screening, Signatera for real-time cancer surveillance, and Prospera, which sharpens the lens on transplant rejection. Over the last three months, the stock has climbed 16.9%, leaving the broader S&P 500 Index's ($SPX) 5.4% gain behind. On May 8, Natera opened the books on its first-quarter, and the results exceeded Wall Street expectations. Investors responded swiftly, with the stock inching up 1.5% the same day. Natera posted $501.8 million in total revenues, a 36.5% year-over-year increase that soared past Wall Street's $443.3 million forecast. Behind those numbers were powerhouse operations. The company processed 855,100 tests during the quarter, up 16.2% year over year. Women's health volumes climbed meaningfully over the fourth quarter, but it was Signatera that stole the spotlight. The personalized, tumor-informed molecular residual disease test reached new heights, recording its highest volume quarter ever. Clinical volumes for Signatera grew 52% year over year, with a sequential gain of roughly 16,005 units over Q4, marking the most significant quarter-on-quarter growth to date. Gross margins landed at 63.1%, reflecting solid cost discipline. Moreover, Natera's net loss narrowed 1% from the year-ago period to $66.9 million. Also, the company managed to trim its loss per share by 10.7% to $0.50, outperforming analysts' projections of a $0.59 loss per share. As for liquidity, the balance sheet remained in good shape. Cash, cash equivalents and restricted cash climbed to $973.8 million, up from $945.6 million on Dec 31, 2024. CEO Steve Chapman has made no secret of the firm's long-term vision. He believes Signatera could ultimately generate over $5 billion in annual revenue, and he emphasized that they are still playing in the shallow end of a much deeper market pool. In a move that reinforced this optimism, Natera has raised its full-year revenue guidance to between $1.94 billion and $2.02 billion. That is a $70 million boost from the midpoint of its earlier outlook, pointing to a 26% year-over-year growth. On the other hand, analysts expect the Q2 2025 loss per share to widen 100% year over year to $0.60. For FY25, the loss per share is projected to increase 37% to $2.10, but FY26 could bring relief, with a forecast 64.8% narrowing to $0.74, hinting that profitability may finally be within reach. Analysts seem to be singing in harmony when it comes to NTRA, marking it with a firm 'Strong Buy' rating. Out of 19 analysts following the stock, 16 have given it an enthusiastic 'Strong Buy' rating, and the remaining three have placed their bets on a 'Moderate Buy.' The average price target of $200.42 represents potential upside of 17.6%. Meanwhile, the Street-High target of $251 hints at a 48% climb from current levels. Such projections do not come lightly and often reflect deep-rooted confidence in future earnings momentum and strategic execution. On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Company makes game-changing breakthrough that could solve common issue with plant-based food — here's what you need to know
Let's be honest: Plant-based protein doesn't always taste great. Even if you love the idea of eating less meat for your health and the planet, the weird aftertaste of some plant-based meats can be hard to ignore. But that might be about to change. According to FoodNavigator USA, the flavor company T. Hasegawa USA has developed a high-tech, natural flavor that tackles the unpleasant "off" notes of plant proteins such as pea and soy. The whole technology (and science) behind it is pretty impressive. When meat sizzles in a pan or bread gets crispy in the toaster, the Maillard reaction creates craveable aromas and flavors. But plant proteins such as soy and pea don't react the same way during cooking, which can leave them tasting bland or, worse, beany and bitter. If companies want people to go for meat alternatives, there's a need to focus on options that taste good and have pleasant textures. As Mark Webster, vice president of sales and marketing at T. Hasegawa, said, "That is where the headwind is." The T. Hasegawa team tackled this problem by developing a natural flavor technology called Plantreact that increases Maillard reactions — the chemical processes that give so-called browned foods their flavors. This innovation doesn't stop with fake meats. The same flavor solution can also recreate creamy, dairy-like notes in alternative milks and other nondairy products. That's huge for people who love the idea of oat or almond milk but miss the full-bodied taste of cow's milk. Plantreact has been in the works for a while, but it's now ready to hit the market. T. Hasegawa is already working with food brands to roll it out in products. Better flavor means plant-based foods are more enjoyable, which makes it easier for more people to cut back on animal products and reduce pollution, conserve water, and shrink their carbon footprints. This tech is already being explored by plant-based brands looking to improve their products, and it may soon appear in alternative meat and dairy products at your local grocery store. Combined with the work of companies such as Meati and Perfect Day, this kind of innovation helps build a future in which eating more sustainably doesn't mean compromising on taste. Why do you eat plant-based foods? The health benefits It's cheaper It's good for the planet I prefer the taste Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.